Login to Your Account

Intercept moves its Ocaliva a step closer to FDA approval

By Mari Serebrov
Regulatory Editor

Thursday, April 7, 2016

The future could get a bit brighter for patients living with primary biliary cirrhosis (PBC), a rare chronic and gradually progressive liver disease that can lead to hepatic fibrosis, cirrhosis, liver failure and potentially death.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription